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Abstract
Background: Dopamine is integral to cognition, learning and memory, and dysfunctions of the frontal cortical
dopamine system have been implicated in several developmental neuropsychiatric disorders. The dorsolateral
prefrontal cortex (DLPFC) is critical for working memory which does not fully mature until the third decade of life.
Few studies have reported on the normal development of the dopamine system in human DLPFC during
postnatal life. We assessed pre- and postsynaptic components of the dopamine system including tyrosine
hydroxylase, the dopamine receptors (D1, D2 short and D2 long isoforms, D4, D5), catechol-O-methyltransferase,
and monoamine oxidase (A and B) in the developing human DLPFC (6 weeks -50 years).
Results: Gene expression was first analysed by microarray and then by quantitative real-time PCR. Protein
expression was analysed by western blot. Protein levels for tyrosine hydroxylase peaked during the first year of life
(p < 0.001) then gradually declined to adulthood. Similarly, mRNA levels of dopamine receptors D2S (p < 0.001)
and D2L (p = 0.003) isoforms, monoamine oxidase A (p < 0.001) and catechol-O-methyltransferase (p = 0.024) were
significantly higher in neonates and infants as was catechol-O-methyltransferase protein (32 kDa, p = 0.027). In
contrast, dopamine D1 receptor mRNA correlated positively with age (p = 0.002) and dopamine D1 receptor
protein expression increased throughout development (p < 0.001) with adults having the highest D1 protein levels
(p ≤ 0.01). Monoamine oxidase B mRNA and protein (p < 0.001) levels also increased significantly throughout
development. Interestingly, dopamine D5 receptor mRNA levels negatively correlated with age (r = -0.31, p =
0.018) in an expression profile opposite to that of the dopamine D1 receptor.
Conclusions: We find distinct developmental changes in key components of the dopamine system in DLPFC over
postnatal life. Those genes that are highly expressed during the first year of postnatal life may influence and
orchestrate the early development of cortical neural circuitry while genes portraying a pattern of increasing
expression with age may indicate a role in DLPFC maturation and attainment of adult levels of cognitive function.
Keywords: DLPFC, postmortem, ADHD, schizophrenia, dopamine receptor, tyrosine hydroxylase, COMT, MAOA,
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Background
The prefrontal cortex (PFC), particularly the dorsolateral
prefrontal cortex (DLPFC), is markedly expanded and
differentiated in the primate brain. In humans, the
DLPFC [1,2] and hence adult level performance in
working memory [3-5] may not fully mature until young
adulthood. The functional integrity of the PFC is sensi-
tive to modulation by catecholamines, particularly dopa-
mine (DA) [6-8]. Indeed, DA is essential to the
development and function of PFC controlled tasks of
working memory, attention, behavioural flexibility, and
planning that comprise executive function [9-12]. Corti-
cal DA neurotransmission involves many genes and syn-
chronised pre- and postsynaptic biochemical processes,
interacting proteins, and enzymes. Several of these genes
and proteins, including those involved in the synthesis
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examined in this study to help define their roles during
postnatal human brain development.
While previous studies have examined parameters of
DA neurotransmission in the developing rodent, pig,
and non-human primate PFC [13-18] few studies have
done so in the human DLPFC over the postnatal life-
span. An early positron emission tomography (PET)
report examined both dopamine receptor D1 (DRD1)
and dopamine D2 receptor (DRD2) in 19-73 year olds
and found an increase in the ratio of DRD1 to DRD2
with increasing age [19]. In a more recent study, in vivo
PET was employed to evaluate DRD1 binding potential
in twenty-eight late childhood/adolescent, and young
adult healthy individuals and found DRD1 binding
potential declined significantly with age in the DLPFC
[20]. The few studies examining the developmental tra-
jectories in human PFC of the DA degradation enzymes,
monoamine oxidase A and B (MAOA, MAOB) [21] and
catecholamine-O-methyltransferase (COMT) [22]
showed developmental changes in protein but did not
investigate mRNA expression. Previously, our laboratory
measured developmental changes for tyrosine hydroxy-
lase (TH) protein expression and DRD1, DRD2, and
dopamine D4 receptor (DRD4) mRNA levels in cortical
layers by in situ hybridization in the DLPFC. TH protein
and DRD2 mRNA expression levels were high early in
life and declined steadily with age whereas DRD1
mRNA expression was highest in young adulthood and
DRD4 expression did not change significantly over the
postnatal lifespan. Unfortunately, this study did not
include any individuals between the ages of 1-13 years
when numerous changes in brain function occur [23-25]
and cognitive processes are developing, particularly in
executive function [26,27].
In fact, it is during the school age period when disrup-
tions in cortical DA neurotransmission are thought to
contribute to the development of attention deficit/
hyperactivity disorder (ADHD) [28]. However, it is likely
that changes in DA neurotransmission in ADHD occur
in the background of normal changes in cortical DA.
Dysfunction of DA has also been implicated in another
developmental neuropsychiatric illness striking in ado-
lescence, schizophrenia [29,30], where working memory
impairments are one of the hallmarks associated with
this disorders [31-34]. Therefore, to better develop stra-
tegies to normalize DA signalling in an age-appropriate
manner, more information is needed about how the DA
system changes in human postnatal life. Utilizing micro-
array technology, changes occurring in the mRNA
expression of dopamine-related gene products were
examined across normal development of the human
DLPFC and further confirmed by quantitative real-time
PCR (qPCR). Because previous reports in the literature
on the developmental patterns of DRD1 mRNA expres-
sion and binding are discrepant, we also included Wes-
tern blot to determine the protein levels of DRD1 as
well as to examine the protein levels of TH, MAOA,
MAOB, and COMT. Our results indicate that the genes
examined here are developmentally regulated over the
protracted maturational period of the human DLPFC.
The changes in gene and protein expression during
postnatal life suggest that DA neurotransmission
requirements of the DLPFC vary throughout develop-
ment and it may be that genes like DRD2 and MAOA
may have multiple functions that vary with age. Abun-
dant DA synthetic capacity in the DLPFC appears to les-
sen as postnatal development progresses yet DA may
t a k eo nam o r et a r g e t e dr o l ei nD L P F Cf u n c t i o n ss u c h
as in cognition, particularly after the first decade of life.
Results
Developmental Cohort and Demographic Variables
The seven age groups for this cohort were matched on
the demographic variables of age, pH, PMI and RIN
(summarised for each group in Table 1). Pearson corre-
lations with the demographic variables and the genes of
interest are detailed in Table 2. pH was found to posi-
tively correlate with DRD1 mRNA, DRD1 and MAOA
proteins (all r > 0.24, p < 0.050) while PMI positively
correlated with DRD2S, DRD5 mRNAs, and TH protein
and was negatively correlated with DRD1, MAOA, and
MAOB proteins (all r > 0.28, p < 0.050). All demo-
graphic variables correlating with genes of interest were
entered as covariates in ANCOVAs examining age
group effects.
Tyrosine Hydroxylase
A TH protein band was detected at the expected ~59
k D as i z eb yW e s t e r nB l o ti ne a c ha g eg r o u p( F i g u r e
1A). Western blots performed for the control protein b-
actin, displayed no significant differences between the
age groups (p = 0.53). TH protein levels varied signifi-
cantly in intensity between the age groups (ANCOVA F
= 8.95, df = 6,57, p < 0.001) and TH levels were highly
and negatively correlated with age (regression r = -0.57,
p < 0.001). Post hoc analysis showed that the neonate (p
Table 1 Developmental cohort demographic information
Age Group (#) Age (Y) pH PMI RIN Gender
Neonate (11) 0.2 ± 0.04 6.50 ± 0.2 22.5 ± 5.1 7.8 ± 1.7 5F/6M
Infant (14) 0.5 ± 0.2 6.58 ± 0.2 16.9 ± 6.4 8.1 ± 1.0 5F/9M
Toddler (10) 2.8 ± 1.1 6.68 ± 0.3 21.2 ± 9.4 7.9 ± 1.1 5F/5M
School Age (9) 9.0 ± 2.7 6.63 ± 0.3 15.1 ± 4.7 7.9 ± 1.2 5F/4M
Adolescent (8) 16.9 ± 0.9 6.75 ± 0.1 15.5 ± 5.3 7.8 ± 0.9 2F/6M
Young Adult (9) 23.2 ± 1.8 6.67 ± 0.2 13.7 ± 8.3 8.6 ± 0.8 3F/6M
Adult (8) 43.4 ± 5.2 6.60 ± 0.3 13.4 ± 4.6 8.2 ± 0.6 3F/5M
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Page 2 of 14< 0.001), infant (p < 0.001), and toddler (p < 0.05)
groups have significantly higher TH protein levels than
the four older groups (Figure 1B). TH protein levels
decrease markedly between the infant and school age
periods and then remain fairly constant into adulthood.
The largest change in expression occurs early in life
with a 67% reduction in TH during the first 5 years
after birth.
Dopamine Receptors
Not all of the dopamine receptors were consistently
detected by microarray in the DLPFC. DRD1 and DRD5
mRNA were expressed at detectable levels whereas
DRD2 and DRD4 mRNA were not consistently
expressed above 50% present (thus data not shown).
The microarray data revealed that opposite to TH
protein, DRD1 mRNA increases significantly with age
(regression r = 0.45, p = 0.002, ANOVA p = 0.014; Fig-
ure 2A), reaching peak expression in the school age per-
iod and then declining slightly after adolescence. The
DRD1 qPCR mRNA data showed a similar pattern to
that of the microarray data with increasing mRNA
expression that weakly correlated with age (r = 0.28, p =
0.039) and there were no significant differences found in
DRD1 mRNA by ANCOVA between the age groups (F
= 1.17, df = 6,45, p = 0.337; Figure 2B).
DRD1 protein expression was strongly correlated with
age (r = 0.60, p < 0.001). Western blot results show the
expected ~ 49 kDa MW band for DRD1 protein at all
time-points examined (Figure 2C). ANCOVA with pH
and PMI revealed a significant effect of age group on
DRD1 protein expression (F = 9.26, df = 6,58, p <
0.001). Post hoc analysis revealed that DRD1 protein
levels rose substantially and steadily from neonatal to
adult levels (Figure 2D). Adults and young adults had
the highest levels of protein that significantly differed
from neonates (both p < 0.001) infants (both p < 0.001),
toddlers (p = 0.004, p = 0.006), and school age (p =
0.012, p = 0.009). The adolescent group also had greater
levels of DRD1 protein compared to the neonates (p <
0.001) and infants (p = 0.004).
Using qPCR, the two DRD2 isoform mRNAs were
easily and reliably detected. Unlike DRD1, DRD2S and
DRD2L mRNA isoforms displayed a significant negative
correlation with age (r = -0.55, p < 0.001; r = -0.42, p <
0.001 respectively). Both DRD2S (ANCOVA F = 7.55, df
= 6,51, p < 0.001) and DRD2L (F = 3.64, df = 6,52, p =
0.004) mRNAs showed dramatic decreases in expression
from the early age groups into adolescence. DRD2S
mRNA expression was highest during the neonatal per-
iod with a substantial 84% downregulation of DRD2S
mRNA between the toddler and school age years (Figure
3A). The neonate (p < 0.001), infant (p < 0.001), and
toddler (p < 0.01) groups had significantly higher
Table 2 Pearsons product moment correlations for
demographic variables and genes of interest
GENE AGE pH PMI RIN
Rprprprp
DRD1 mRNA 0.28 0.039 0.108 0.439 0.33 0.014 0.047 0.737
Protein 0.60 <
0.001
-0.28 0.021 0.33 0.006
DRD2S mRNA -0.55 <
0.001
0.26 0.042 -0.13 0.317 -0.08 0.538
DRD2L mRNA -0.42 <
0.001
0.1 0.457 0.03 0.848 0.07 0.612
DRD4 mRNA -0.30 0.057 0.02 0.898 -0.31 0.041 0.23 0.130
DRD5 mRNA -0.33 0.012 0.26 0.049 -0.18 0.174 -0.07 0.622
TH Protein -0.57 <
0.001
0.37 0.002 -0.06 0.658
MAOA mRNA -0.28 0.030 0.09 0.479 -0.01 0.925 -0.05 0.706
Protein 0.76 <
0.001
-0.43 <
0.001
0.24 0.044
MAOB mRNA 0.49 <
0.001
-0.16 0.203 0.01 0.925 0.06 0.646
Protein 0.5 <
0.001
-0.34 0.005 0.04 0.744
COMT mRNA -0.11 0.386 0.09 0.475 -0.15 0.242 0.04 0.750
Protein -0.28 0.027 0.15 0.243 0.40 <
0.001
Figure 1 (A) TH Western blot results demonstrating the
expected 59 kDa band in representative cases from 6 of 7 age
groups. A = Adult, Ad = Adolescent, S = School Age, T = Toddler, I
= Infant, N = Neonate. (B) TH protein expression is normalized to
the adults. Post hoc analysis reveals the decline in TH with
increasing age compared to neonate and infant groups as
compared to all other age groups. ** = p < 0.01; * = p < 0.05.
Rothmond et al. BMC Neuroscience 2012, 13:18
http://www.biomedcentral.com/1471-2202/13/18
Page 3 of 14DRD2S mRNA from that of school age through adult
groups. We detected significant differences between the
neonate and toddler groups’ DRD2L mRNA which both
had higher levels compared to adolescent (p < 0.001; p
= 0.009), young adult (p = 0.006; p = 0.041) and adult
(p = 0.001; p = 0.012; Figure 3B) age groups.
The DRD4 qPCR gene expression data was quite vari-
able and was not significantly correlated with age (r =
-0.30, p = 0.057) nor did we detect significant differ-
ences in DRD4 mRNA between the age groups (F =
1.71, df = 6,34, p = 0.147; Figure 4A).
Figure 2 (A) DRD1 microarray (p = 0.002) and (B) qPCR mRNA
results show a similar pattern of increasing expression with
age (p = 0.037) until adulthood. (C) A representative Western blot
for 6 of 7 age groups with the expected protein band at ~49 kDa.
A = Adult, N = Neonate, S = School Age, Y = Young Adult, T =
Toddler. (D) Protein expression increased robustly with age and
appears to plateau during early adulthood. Adults and young adults
had the highest levels of protein compared to neonates (both p <
0.001) infants (both p < 0.001), toddlers (p = 0.004, p = 0.006), and
school age (p = 0.012, p = 0.009). Adolescents had greater levels of
DRD1 protein than neonates (p < 0.001) and infants (p = 0.004). **
p ≤ 0.01, * p ≤ 0.05.
Figure 3 ( A )D R D 2 S( p<0 . 0 0 1 )a n d( B )D R D 2 L( p=0 . 0 0 3 )
qPCR mRNA results. (A) Neonates (p < 0.001), infant, and toddler
groups (p < 0.01) had greater DRD2S mRNA than that of school
age, adolescent, young adult & adult age groups. (B) DRDL mRNA
followed a similar developmental pattern with the neonatal age
group having the higher levels of DRD2L mRNA compared to
school age (p = 0.050), adolescent (p < 0.001), young adult (p =
0.006), and adult age groups (p = 0.001). The toddler group had
greater DRD2L mRNA than adolescents (p = 0.009), young adults (p
= 0.041), and adults (p = 0.012). *** p ≤ 0.001, ** p ≤ 0.01, * p ≤
0.05.
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that expression changed very little over the lifespan
(regression r = 0.15, p = 0.324, ANOVA p = 0.277; Fig-
ure 4B). However, the DRD5 qPCR analysis showed a
slight negative correlation with age (r = -0.33, p =
0.012) although we did not find statistically significant
differences overall between the age groups (F = 1.14, df
= 6,48, p = 0.354; Figure 4C).
Dopamine Metabolism
Microarray analyses of mRNA encoding three enzymes
involved in dopamine inactivation, MAOA, MAOB, and
COMT were all found to significantly change expression
levels during development.
MAOA
Regression analysis of the microarray data revealed that
MAOA mRNA was highly expressed in the neonate and
infant groups and then decreased significantly with age
(regression r = -0.56, p < 0.001, ANOVA p < 0.001; Fig-
ure 5A). Similarly, qPCR revealed a slight negative cor-
relation of MAOA with age (r = -0.28, p = 0.030) and
the mRNA changed significantly between the age groups
(ANOVA F = 6.30, df = 6,55, p < 0.001; Figure 5B). Post
hoc analysis showed that the neonates had significantly
higher levels of mRNA compared to the infant (p =
0.003), toddler, school age (both p < 0.001), adolescent
(p = 0.001), young adult and adult (both p < 0.001) age
groups. Infants also significantly differed from the
s c h o o la g e( p=0 . 0 3 1 )a n dy o u n ga d u l t( p=0 . 0 2 8 )a g e
groups.
Western blot confirmed MAOA protein expression at
the ~61 kDa MW band for all age groups (Figure 5C).
However, in stark contrast to the decrease with aging of
MAOA mRNA, MAOA protein positively correlated
with age (r = 0.76, p < 0.001) with significant differences
found between the age groups (F = 27.08, df = 6,59, p <
0.001; Figure 5D). The highest level of MAOA protein
was observed in the young adult group that significantly
differed from neonates, infants, toddlers, school age (all
p < 0.001) and the adolescent group (p = 0.010). In fact,
MAOA protein levels more than doubled between the
school age and adolescent age groups (p < 0.001). Ado-
lescents and adults had greater MAOA protein com-
pared to the neonatal, infant, toddler, and school age
groups (p < 0.01).
MAOB
Opposite to the MAOA mRNA expression which
decreased with age, microarray analysis revealed that
MOAB mRNA increased dramatically with age peaking
in adulthood (regression r = 0.83, p < 0.001, ANOVA p
< 0.001; Figure 6A). The qPCR study confirmed that
Figure 4 (A) DRD4 qPCR mRNA expression in postnatal life (p
= 0.147). (B) Results for the microarray DRD5 mRNA showed very
little overall age related expression (regression p = 0.32). (C) DRD5
qPCR mRNA correlated negatively with age (p = 0.012) with no
significant differences between the age groups (p = 0.353).
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rise in expression with aging (regression p < 0.001); (B) qPCR
mRNA results display similar pattern of up-regulation with age
(p = 0.001). Post hoc analysis revealed the adult group possessed
significantly higher mRNA compared to the neonate (p = 0.002),
infant, toddler (both p < 0.001), and adolescent (p = 0.014) age
groups. Young adults also had greater MAOB mRNA compared to
the neonates (p = 0.023), infants (p = 0.007), and toddlers (p =
0.009) while the school age group had significantly higher mRNA
than infants (p = 0.041) and toddlers (p = 0.045). (C) A
representative Western blot indicating the identifying band of
MAOB protein at 60 kDa in most age groups. N = Neonate, I =
Infant, T = Toddler, Y = Young Adult, S = School Age, A = Adult, Ad
= Adolescent. (D) MOAB protein expression peaks in adolescence (p
< 0.001) and is much more abundant in both young adults and
adults compared to the neonate (p < 0.001), infant (p < 0.01), and
toddler (p ≤ 0.01) age groups. ** p ≤ 0.01, * p ≤ 0.05.
Figure 5 (A) MAO-A microarray mRNA expression significantly
changed with age (regression p < 0.001) with school age
having the lowest mRNA levels; (B) Post hoc analysis of qPCR
mRNA data confirmed that the school age group had the
lowest expression (p < 0.001) and along with the young adult
(p < 0.001) age group had reduced mRNA compared to the
neonate group. (C) A representative Western blot with the
expected 61 kDa band for MAOA protein, and additional band at ~
52 kDa. I = Infant, N = Neonate, T = Toddler, S = School Age, Ad =
Adolescent, Y = Young Adult, A = Adult. (D) There is a dramatic
difference in protein expression between age groups and opposite
to that of MAOA mRNA. High immunoreactivity was observed in
the older age groups, with young adults having significantly greater
MAOA protein compared to neonates, infants, toddlers, school age
groups (p < 0.001) as did the adolescents and adults (p < 0.01). ***
p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05.
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(r = 0.49, p < 0.001) and significantly changed between
age groups (F = 4.22, df = 6,56, p < 0.001; Figure 6B).
Post hoc analysis showed that adults had greater MAOB
mRNA levels compared to neonatal (p = 0.002), infant,
toddler (both p < 0.001), and adolescent (p = 0.014) age
groups while the young adults also had higher levels of
mRNA to that of neonates (p = 0.023), infants (p =
0.007), and toddlers (p = 0.009) as did the school age
group compared to infants (p = 0.041) and toddlers (p =
0.045).
MAOB immunoreactivity with the expected ~60 kDa
MW band was present at all ages (Figure 6C). As with
the mRNA, the MAOB protein levels increased signifi-
cantly with age (r = 0.50, p < 0.001) and differed
between the age groups (ANCOVA F = 4.79, df = 6,60,
p < 0.001) with peak MAOB protein expression in the
adolescent group. Post hoc analysis showed that the
adolescent group had significantly higher levels than the
neonate, infant, toddler (all p < 0.001) and school age (p
= 0.031) age groups. The neonates had the lowest pro-
tein levels of all age groups with significant differences
compared to the school age (p = 0.018), adolescent,
young adult and adult (all p < 0.001) age groups (Figure
6D).
COMT
The microarray data showed COMT mRNA decreased
throughout development with slightly higher levels of
expression at birth that gradually declined with age
(regression r = -0.33, p = 0.024, ANOVA p = 0.252; Fig-
ure 7A). The qPCR mRNA study also showed a signifi-
cant decrease in COMT expression between the age
groups (ANOVA F = 2.83, df = 6,58, p = 0.018; Figure
7B) but did not correlate with age (r = -0.11, p = 0.386).
Neonates had significantly greater COMT mRNA than
the infant (p = 0.006), toddler (p = 0.013), school age (p
= 0.005), adolescent (p = 0.002), young adult (p = 0.001)
age groups.
Western blot for COMT showed two major bands of
protein with the ~30 kDa membrane bound protein
forming the most robust band and another band form-
ing at ~24 kDa consistent with the soluble protein form.
Both bands were present in all age groups (Figure 7C).
Age showed a weak negative correlation with expression
for the ~30 kDa COMT protein (r = -0.28, p = 0.027)
but not with the ~24 kDa protein (r = -0.15, p = 0.238).
There were no significant differences for age group with
either COMT protein band (p > 0.05; Figure 7D).
Discussion
Various components of the dopamine system displayed
distinct and robust changes in both transcript and pro-
tein levels during postnatal development. Thus, the
Figure 7 (A) COMT microarray (regression p = 0.025) and (B)
qPCR mRNA results (p = 0.018) reveal a subtle pattern of early
high COMT expression. The neonatal group had mRNA levels 35-
60% higher than all other age groups (p ≤ 0.001-p ≤ 0.05). (C) A
representative Western blot gel depicts two bands at ~30 kDa &
~24 kDa of COMT protein that is consistent with both membrane
bound (32 kDa) and the soluble form (24 kDa); N = Neonate, I =
Infant, T = Toddler, S = School Age, Ad = Adolescent, Y = Young
Adult, A = Adult. (D) The COMT protein results follow a pattern
similar to the mRNA data with higher expression early in life that
gradually declines over time but was not statistically significant. * p
≤ 0.05.
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developmental profiles in relation to DA synthesis,
receptor signalling, and DA breakdown which all change
as humans grow and mature. Many DA receptor
mRNAs showed dynamic changes across development.
The most commonly observed developmental pattern
was to have the highest expression in the youngest age
groups, within the first five years of life followed by a
decline in expression with age. The expression of
DRD2S, DRD2L, and DRD5 mRNAs all displayed this
pattern of downregulation with maturation as did TH
and MAOA mRNA. MAOA was the only molecule that
showed a pronounced decoupling between mRNA and
protein expression with the protein showing an increase
with age. MOAB and DRD1 (mRNA and protein)
showed a gradual increase in expression with age. Inter-
estingly, DRD1 was unique among the dopamine recep-
tors in terms of its developmental profile and our
results suggest that there is an increased role for DRD1
as the human cortex matures.
Previous reports suggest that by early adulthood
DRD1 is the most prevalent receptor in the PFC fol-
lowed by DRD2, DRD4, and DRD5 expression [18,35].
The results reported here show that while all other
receptors are decreasing with age, DRD1 mRNA and
protein levels are increasing in postnatal life. The
increase in DRD1 mRNA expression with age is consis-
tent with our earlier report in a different cohort that
showed an increase in DRD1 mRNA expression in mul-
tiple cortical layers in the DLPFC during development
[36] with similar peaks of expression during adolescence
and young adulthood. As more age groups are repre-
sented in this study our results here suggest that a sub-
stantial increase in DRD1 mRNA is evident even earlier
at around the time of school age years where mRNA
levels were very similar to that of adolescent and young
adult age groups.
The DRD1 protein peak in expression appears to
occur a few years later in life than that of mRNA
expression. DRD1 is critical to PFC cognitive function-
ing and in particular working memory [37] and these
cognitive processes may not fully mature until the third
decade of life [38,39] Thus, the change in DRD1 from
periadolescence into young adulthood happens during a
time in development when the cortex and our cognitive
behaviour are also maturing suggesting that DA-DRD1
may have an integrative role in higher cortical function.
While DRD1 mRNA and protein expression is low
early in cortical development, DRD5 expression is at its
highest expression. This pattern of DRD5 expression
which is opposite to the DRD1 pattern is interesting,
given that both receptors are almost indistinguishable
pharmacologically [40]. While all of the DA receptors
have been shown to play some role in cognition [41,42],
DRD5 is consistently co-localised with DRD1 on pyra-
midal neurons in the PFC [43]. DRD5 has a ten-fold
higher affinity for DA as compared to DRD1 [40] and
our finding of increased early expression of DRD5 sug-
gests that this receptor may play a more salient role in
early postnatal cortical development than DRD1. Thus,
it may be that each receptor provides a differential con-
tribution to DA’s influence over pyramidal neurons,
dependent upon whether it is in early life or at matura-
tion [44].
To date, there are no published reports of the DRD2
short and long isoforms in developing primate or
human PFC and results in the developing rodent cere-
bral cortex have been inconsistent. A recent postnatal
s t u d yi nr o d e n tc o r t e xs h o w e dD R D 2 Sa n dD R D 2 L
mRNA expression peaking in early development which
is similar to our results [45]. In contrast, Mack et al.,
(1991) reported that in whole rat brain extracted
mRNA, both isoforms increasee x p r e s s i o nt h r o u g h o u t
pre- and postnatal development with the highest levels
occurring in adulthood [46]. A third study examined the
isoforms in whole brain and found DRD2S peaking at
14 days (approximately infant age in humans) and
DRD2L at 28 days (approximately school age years) with
mRNA levels declining thereafter [47]. We find that in
human PFC, DRD2 transcripts exhibit high expression
at birth that declines with age. Our studies show that
the developmental decrease in DRD2S (before school
age) may occur prior to DRD2L (after school age) sug-
gesting that during the school age period in normal chil-
dren the balance of DRD2 isoform signalling may favour
the long isoform of the receptor. Our earlier study
examining DRD2 mRNA in PFC showed that the
mRNA was greatest during the first few months of post-
natal life in all cortical layers. Increased DRD2 mRNA
early in development that is localised to both excitatory
[48,49] and inhibitory [50,51] neurons, may enable DA
to modulate neuronal cell types, especially immature
GABA neurons because interneurons, which show pro-
tracted maturation, [52] are still differentiating in
human DLFC postnatally [53]. Also there is still consid-
erable growth of cell soma, dendrites, and synapses
occurring within the first five years of life [54] when
DRD2 and DRD5 mRNA levels are high and DRD1
levels are lowest. Since DRD2 is negatively coupled to
adenylate cyclase, high DRD2 levels may be important
for attenuating pyramidal neuron activity when DRD5 is
high early in life.
Rodent studies have shown varied results in the devel-
opmental pattern of DRD4 mRNA expression [18,47,55]
as have human studies [56,57]. The results presented
here suggest that DRD4 mRNA expression may be vari-
able throughout postnatal life. Our previous postnatal
study of laminar patterns of DRD4 expression did not
Rothmond et al. BMC Neuroscience 2012, 13:18
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that the highest levels of DRD4 mRNA expression
occurred in the infant group, particularly in layer V and
VI [36]. The lack of robust change in DRD4 we find
here suggests that age may not be a strong regulator of
DRD4 or that maintaining fairly steady DRD4 is impor-
tant throughout postnatal life.
As anticipated, TH protein is in greater abundance
during the first decade of life and recedes with age [36].
I tm a yb et h a tT Ha n dh e n c eD Aa r en e c e s s a r yi n
greater abundance during prenatal and early postnatal
brain development in order to stimulate the establish-
ment of other neurons and connections. Indeed, TH
fibres appear early in embryonic cortex in the telence-
phalic wall as early as gestational week 8 in humans
[58]. The crucial role of TH in overall development is
reinforced by the fact that TH knockout mice do not
survive beyond E15.5 [59]. As the PFC develops postna-
tally, the amount of TH and DA synthesis required may
be much less. Our results of high levels of TH early in
life in the human DLPFC, now found in two distinct
cohorts [36], suggests that there is a large synthetic
demand for dopamine early in life when cortical pyrami-
dal neurons (dendritic and appositions) are still matur-
ing [15] and inhibitory interneurons are still migrating
and differentiating [53]. It is also possible that while TH
and thus DA synthesis decline, DA innervation becomes
more targeted and circuitry refined so that less DA is
required to be effective [15].
Another way to change the parameters of DA action is
to change the time course of action. The genes responsi-
ble for the inactivation via degradation of DA were
f o u n dt ov a r yw i d e l yi nt h e i rdevelopmental profiles,
with very significant and distinct patterns of expression
and in some cases completely opposite profiles from
transcription to protein. MAOA mRNA and COMT
mRNA and protein exhibited the highest levels of
expression in the earliest age groups, suggesting that
DA synthesis may be highest early in life and that
increased metabolism of DA (via MAOA) may be
required to maintain a biochemical balance. But MAOA
protein, MAOB mRNA and protein levels increased
with age suggesting that later in life there may be
increased breakdown of DA through MAOs and that
DA’s action may be temporarily restricted.
It is not clear why MAOA mRNA expression declined
across development whereas MAOA protein increased
throughout development to reach peak levels in young
adulthood. Our findings do not appear spurious given
that the MAOA mRNA data was confirmed in both the
microarray and qPCR studies and the Western results
show the immunoreactive band of the expected size and
to be robustly expressed. Thus the MAOA mRNA may
not be efficiently translated into protein or the MAOA
protein may be very unstable early in life. It is also pos-
sible that there is a presynaptic increase in MAOA pro-
tein due to mRNA that is synthesized in the brain stem
and the protein is transported to axon terminals such
that mRNA and protein levels would appear uncoupled.
Previous binding studies of MAOA in rodent suggest a
profile similar to our protein results where MAOA
expression increases from P0, plateau around P21 and
gradually declines through adulthood [60-62]. In addi-
tion, mRNA studies in the rodent are consistent with
our mRNA results where MAOA expression declines
[63]. However, the low level of MAOA protein in early
postnatal life is in contrast to published data on radiola-
beled MAOA activity in postmortem human frontal cor-
tex that showed the highest MAOA activity in humans
less than one year of age [21]. Further study is needed
to resolve if species differences exist or if discrepancies
in the developmental profiles of MAOA mRNA, protein
expression, and activity levels exist.
Unlike MAOA, MAOB mRNA and protein both
increase throughout postnatal life. Having low levels of
MAOA protein and MAOB protein expression early in
life while DA synthesis is presumably highest and DA
breakdown slower due to lower levels of MAOA protein
and MAOB protein with perhaps only COMT at higher
levels, suggests that the overall actions of dopamine may
be prolonged in the infant PFC where presumably more
DA is available to be released and where there may be a
delay in degradation through MAOA and MAOB. This
is particularly true for MAOB which has been shown to
have a higher affinity for DA than MAOA [64] and both
MOAs have affinities for other catecholamines as well
as serotonin and this may have a more broad influence
over monoamine developmental availabilities. Hence,
MAOB may play an increasingly significant role in corti-
cal DA metabolism at maturation and in adult life.
COMT mRNA is more prominent in the PFC than in
subcortical brain regions [65]. Although the noradrena-
line transporter [66,67], vesicular monoamine transpor-
ter 2 (VMAT2) and MAO [64,68] contribute to DA
elimination, COMT is responsible for approximately ~
60% of all DA degradation in the PFC [69] and our
results suggest that this may be higher earlier in postna-
tal life. The role of COMT in maintaining DA neuro-
transmission is clearly an important one. Indeed, the
TH data would indicate that DA synthesis and presum-
ably DA itself, is extremely abundant early in life with
slightly higher levels of COMT protein. COMT mRNA
and protein displayed a decrease in expression. The
higher gene expression of COMT early in postnatal
development is consistent with a previous report in rat
w h e r eC O M Tm R N Aw a sh i g h l yv i s i b l ei nc o r t e x ,h i p -
p o c a m p u s ,a n ds t r i a t u ma td a yP 1a n dw i t hh i g h e r
mRNA levels at P1 in hypothalamic nuclei that
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COMT mRNA and protein levels alone predict COMT
activity. In a previous study in human DLPFC we found
increasing COMT enzymatic activity with age was asso-
ciated with the COMT Val
158Met polymorphism [22],
although genotype effects on mRNA levels [71,72] and
protein [22,73] levels are not consistent. Further studies
are needed to understand the developmental relation-
ship between COMT genotype, COMT synthesis,
COMT activity, and DA levels.
Conclusions
Taken together these results indicate that pre- and post-
synaptic genes of the dopamine system studied here are
developmentally regulated over the protracted matura-
tional period of the human DLPFC. The changes in
gene and protein expression during postnatal life sug-
gest that DA neurotransmission requirements of the
D L P F Cv a r yt h r o u g h o u td e v e l o p m e n ta n di tm a yb e
t h a tg e n e sl i k eD R D 2a n dM A O Am a yh a v em u l t i p l e
functions that vary with age. Several genes that showed
high early gene expression had their lowest levels of
expression around the school age and adolescent periods
(DRD2S, DRD2L, and MAOA). Genes that had
increased expression with age may be associated with
healthy adult cognition and behaviour. Abundant DA in
the DLPFC appears to lessen as postnatal development
progresses yet DA may take on a more targeted role in
DLPFC functions such as in cognition, particularly after
the first decade of life. Our results underscore the need
for greater understanding of how the drugs used to treat
ADHD, which increase cortical DA neurotransmission
and are typically given in school age children [74], and
schizophrenia, which block DA neurotransmission
(DRD2) and are often given in adolescence, [75] may
alter these normal developmental trajectories.
Methods
Subjects
Postmortem samples from DLPFC (Brodmann’s area 46)
from 69 cases ranging in age from 6 weeks to 49 years
were obtained from the National Institute of Child
Health and Development Brain and Tissue Bank for
Developmental Disorders (NICHD Contract NO1-HD8-
3283; IRB approval H-20765) [76]. Briefly, the cases
included 41 males, 28 females, 37 African Americans, 30
Caucasians, and 2 Hispanics, and were grouped as neo-
nates (0.1-0.24 years), infants (0.25 - 0.9 years), toddlers
(1-5 years), school-age (6-12 years), adolescents (14-17
years), young adults (20-25 years) and adults (35 -50
years). The age groups were matched for mean post-
mortem interval (PMI) and pH. All subjects were free of
neurological and psychiatric symptoms at the time of
death.
RNA Extraction, Purification, and Quality Assessment
In RNase-free conditions, 0.5 g of grey matter was
excised from a frozen 3 mm coronal DLPFC tissue slice
of each case then pulverized and weighed while frozen,
and stored at -80°C. Total RNA was extracted from ~
300 mg of DLPFC using a modified TRIzol
® Reagent
extraction procedure as previously described [77]. RNA
integrity number (RIN) measurements were calculated
for each sample and are listed in Table 1 using the Agi-
lent 2100 Bioanalyzer system. Cases were excluded from
the qPCR and microarray studies with a RIN value
below 6.0. Samples used for the microarray study were
further purified through a Qiagen RNeasy Mini kit (Cat
# 74104, Qiagen Inc.) according to the manufacturer’s
protocol. For the DRD1 and DRD5 qPCR experiments,
an aliquot of each total RNA sample underwent DNase
treatment using DNA-free (Cat # AM1906, Ambion,
Life Technologies, Inc.) to remove any genomic DNA
contamination.
Quantitative real-time PCR (qPCR)
3 μg of RNA from each sample was converted into
cDNA using the First-Strand SuperScript II
® synthesis
system for qPCR (Cat # 11904-018, Invitrogen, Life
Technologies, Inc.) following the manufacturer’sp r o t o -
col. qPCR reactions were performed on an ABI Prism
7900 Fast sequence detection system in a 384-well for-
mat (Applied Biosystems, Life Technologies, Inc.) using
the TaqMan gene expression system (part numbers for
each assay are listed in Table 3). Housekeeping genes
that did not change expression with development were
used for the geomean calculations: beta-2-microglobulin
(B2M), hydroxymethylbilane synthase (HMBS), glucuro-
nidase, beta (GUSB), and peptidylprolyl isomerase A
(PPIA). The housekeeping genes and the subsequent
geomeans were tested by Pearsons product moment cor-
relations and did not significantly correlate to any age
Table 3 Applied Biosystems TaqMan gene expression
assay part numbers
Gene Name (Gene Symbol) Taqman Assay
Glucuronidase, beta (GUSB) Hs99999908_m1
Peptidylprolyl isomerase A (Cyclophilin A-PPIA) Hs99999904_m1
Beta-2-microglobulin (B2M) Hs99999907_m1
Hydroxymethylbilane synthase (HMBS) Hs00609297_m1
Catechol-O-methyltransferase (COMT) Hs00241349_m1
Dopamine receptor D1 (DRD1) Hs00265245_s1
Dopamine receptor D2 long isoform (DRD2L) Hs01024460_m1
Dopamine receptor D2 short isoform (DRD2S) Hs01014210_m1
Dopamine receptor D4 (DRD4) Hs00609526_m1
Dopamine receptor D5 (DRD5) Hs00361234_s1
Monoxidase A (MAOA) Hs00165140_m1
Monoxidase B (MAOB) Hs011006243_m1
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triplicate and measured in the same plate for each gene
of interest. Triplicate outliers were determined by
Grubbs Test (GraphPad), removed, and the mean recal-
culated. NTC wells resulted in no detectable signal. The
change in mRNA expression was calculated using the
average measurement of the adult cases as the calibrator
for the target genes and normalized to the geometric
mean of the housekeeping genes for each experiment
using the ΔΔCt method [78].
Microarray RNA Study
The microarray study contained six-eight cases in each
of seven age groups totalling forty-eight cases. RNA was
processed through the Affymetrix preparation protocol
[http://www.affymetrix.com, [79]] hybridized to HG-
U133 version 2.0+ (GeneChips, Affymetrix) as previously
described [80]. Affymetrix Microarray Suite (MAS 5.0)
was used for image processing and data acquisition. The
Bioconductor package was used to compute normalized
expression values from the Affymetrix ‘.cel’ files.
Protein Extraction and Quantitative Determination
Protein was extracted from approximately ~ 100 mg of
DLPFC, thawed on wet ice, and homogenized with Tris-
glycerol extraction buffer in the presence of protease
inhibitors at the ratio of 10 mL of buffer to 1 g of tissue
as previously described [81]. Aliquots (50 μl) of the sam-
ples were placed into individual microcentrifuge tubes
and stored at -80°C.
To quantitate protein expression, 1-10.6 μg( T a b l e4 )
of total protein determined by Bradford assay from each
case was assessed by Western blot. Samples were run
on 10% polyacrylamide gels at 120 V for 2 hr and
blotted onto a nitrocellulose membrane for 1.5 hr at 30
V. Primary antibody dilutions (Table 4) were prepared
in 3% normal goat (Vector Labs) and 2% non-fat dry
milk in TBS-T and then incubated for 16-72 hr on an
orbital shaker at 4°C. Following washes in TBS-T, sec-
ondary antibody dilutions were prepared in 4% normal
g o a to rd o n k e ys e r u mi nT B S - Ta n da p p l i e df o r2h ra t
RT. The gels were rinsed, exposed to ECL plus chemilu-
minescent substrate detection reagents (Amersham/GE
Healthcare) for the visual detection of the immunoposi-
tive bands and finally exposed to Kodak Bio-Max MR
film. Values measured from each sample were normal-
ized to the adults (100%) run on the same gel.
Statistical Analyses
Regression and Analysis of Variance (ANOVA) statisti-
cal analyses for the Affymetrix microarray data was per-
formed using R and Bioconductor software. Genes that
did not reach criteria for 50% present or that had
expression levels below the limit of detection (50 units)
were not reported in microarray results. Statistical ana-
lyses for qPCR and Western blot data were conducted
using Statistica (StatSoft Inc., 2005, Statistica ver 7.1).
Pearsons product moment correlation analyses were
conducted for the impact of demographic variables (age,
p H ,P M I ,R I N )o nt h eg e n e so fi n t e r e s t .A N O V A sw e r e
performed to assess age group differences for each gene
of interest. ANCOVAs were performed where significant
correlations with demographic variables were detected.
Fisher LSD post hoc tests were used to determine signif-
icant differences between the group means. Prior to
qPCR statistical analyses the normalized dataset was
assessed for population outliers within each develop-
mental group (Grubbs Test, GraphPad). Significance
was set at p ≤ 0.050.
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Table 4 Primary (1
o) and secondary (2
o) antibody (Ab) part numbers, dilutions, and incubation information
1
o Antibody
(Conc)
Company
(Part No)
2
o Antibody
(Conc)
Company
(Part No)
Protein
(μg)
Incubation
Time (hrs)
COMT Rabbit IgG
(1:3000)
Millipore
(AB 5873)
Goat anti-rabbit
(1:10000)
Millipore
(AP307P)
1.0 24
DRD1 Rabbit IgG
(1:1000)
ABCAM
(40653)
Goat anti-rabbit
(1:100000)
Millipore
(AP307P)
8.5 18
MAOA (C19) Goat
IgG (1:1000)
Santa Cruz
(sc-18396)
Donkey anti-goat (1:100000) Santa Cruz
(sc-2020)
6.0 18
MAOB (D16) Rabbit
IgG (1:3000)
Santa Cruz
(sc-18402)
Donkey anti-goat
(1:100000)
Santa Cruz
(sc-2020)
3.0 18
TH Mouse IgG
(1:1000)
Millipore
(MAB 318)
Goat anti-mouse
(1:10000)
Millipore
(AP124)
10.6 72
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